{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:38:05Z","timestamp":1787870285949,"version":"build-2784847793"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ijid.2022.11.012","type":"journal-article","created":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T15:09:53Z","timestamp":1668352193000},"page":"39-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N\/R mutation"],"prefix":"10.1016","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8096-3063","authenticated-orcid":false,"given":"Mao-Song","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0629-9790","authenticated-orcid":false,"given":"Cheng-Pin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hsiang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Eng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Jen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7871-4706","authenticated-orcid":false,"given":"Tung-Che","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Ti","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Huang","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.11.012_bib0001","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2022.11.012_bib0002","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/QAI.0000000000002454","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) from dolutegravir (DTG)+F\/TAF or DTG+F\/tenofovir disoproxil fumarate (TDF) in the presence of pre-existing NRTI resistance","volume":"85","author":"Acosta","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2022.11.012_bib0003","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/jac\/dkz347","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V\/I","volume":"74","author":"Andreatta","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2022.11.012_bib0004","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2352-3018(14)00061-7","article-title":"Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the second-LINE trial: an exploratory analysis","volume":"2","author":"Boyd","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijid.2022.11.012_bib0005","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s40121-021-00449-z","article-title":"Meta-analysis of efficacy and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide among people living with HIV","volume":"10","author":"Chen","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijid.2022.11.012_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106631","article-title":"Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens","volume":"60","author":"Chen","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2022.11.012_bib0007","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s40265-018-1010-7","article-title":"Bictegravir\/Emtricitabine\/Tenofovir alafenamide: a review in HIV-1 infection","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ijid.2022.11.012_bib0008","unstructured":"EACS Guidelines version 11.0, October 2021 https:\/\/www.eacsociety.org\/media\/final2021eacsguidelinesv11.0_oct2021.pdf"},{"key":"10.1016\/j.ijid.2022.11.012_bib0009","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.3390\/v6104080","article-title":"The lysine 65 residue in HIV-1 reverse transcriptase function and in nucleoside analog drug resistance","volume":"6","author":"Garforth","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.ijid.2022.11.012_bib0010","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1128\/AAC.01380-09","article-title":"International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase","volume":"54","author":"Grant","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.11.012_bib0011","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/QAI.0b013e3181b06125","article-title":"Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria","volume":"52","author":"Hawkins","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2022.11.012_bib0012","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/S2352-3018(16)30011-X","article-title":"Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study","volume":"3","author":"La Rosa","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijid.2022.11.012_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106403","article-title":"Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV","volume":"58","author":"Lee","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2022.11.012_bib0014","series-title":"Abstracts From CROI 2022, Conference on Retroviruses and Opportunistic Infections","first-page":"483","article-title":"Dolutegravir wiht recycled nRTIs siis noninferior to PI-based ART: VISEND trial. [CROI Abstract 135]","author":"Mulenga","year":"2022"},{"key":"10.1016\/j.ijid.2022.11.012_bib0015","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00002030-200206140-00004","article-title":"Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF","volume":"16","author":"Margot","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2022.11.012_bib0016","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1468-1293.2006.00404.x","article-title":"Study 903 Team. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903","volume":"7","author":"Margot","year":"2006","journal-title":"HIV Med"},{"key":"10.1016\/j.ijid.2022.11.012_bib0017","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081823","article-title":"Viro-immunological, clinical outcomes and costs of switching to BIC\/TAF\/FTC in a cohort of people living with HIV: a 48-week prospective analysis","volume":"10","author":"Mazzitelli","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ijid.2022.11.012_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106343","article-title":"HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance","volume":"57","author":"Mbhele","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2022.11.012_bib0019","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/cid\/ciab583","article-title":"Transmitted drug resistance among human immunodeficiency virus (HIV)-1 diagnoses in the United States, 2014\u20132018","volume":"74","author":"McClung","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.11.012_bib0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/135965350801300212","article-title":"Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database","volume":"13","author":"McColl","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijid.2022.11.012_bib0021","first-page":"22","article-title":"K65R, TAMs and tenofovir","volume":"6","author":"Miller","year":"2004","journal-title":"AIDS Rev"},{"key":"10.1016\/j.ijid.2022.11.012_bib0022","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/381784","article-title":"Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients","volume":"189","author":"Miller","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2022.11.012_bib0023","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijid.2022.11.012_bib0024","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijid.2022.11.012_bib0025","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials","volume":"7","author":"Orkin","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijid.2022.11.012_bib0026","doi-asserted-by":"crossref","first-page":"D371","DOI":"10.1093\/nar\/gkl855","article-title":"The HIV positive selection mutation database","volume":"35","author":"Pan","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ijid.2022.11.012_bib0027","series-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","year":"2022"},{"key":"10.1016\/j.ijid.2022.11.012_bib0028","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1086\/505711","article-title":"Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level","volume":"194","author":"Parikh","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2022.11.012_bib0029","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/QAD.0b013e3281ac229b","article-title":"Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase","volume":"21","author":"Parikh","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2022.11.012_bib0030","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2352-3018(17)30065-6","article-title":"Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial","volume":"4","author":"Paton","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijid.2022.11.012_bib0031","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa2101609","article-title":"Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV","volume":"385","author":"Paton","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.11.012_bib0032","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3018(22)00092-3","volume":"9","author":"Paton","year":"2022","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijid.2022.11.012_bib0033","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1","volume":"44","author":"Petropoulos","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.11.012_bib0034","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00430-015-0448-4","article-title":"Prevalence of K65R in patients treated with tenofovir disoproxil fumarate: recommendations based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD)","volume":"205","author":"Reinheimer","year":"2016","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.ijid.2022.11.012_bib0035","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society-USA panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2022.11.012_bib0036","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus","volume":"73","author":"Sax","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.11.012_bib0037","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1086\/505356","article-title":"Rationale and uses of a public HIV drug-resistance database","volume":"194","author":"Shafer","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2022.11.012_bib0038","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/infdis\/jix544","article-title":"Prevalence of pre-antiretroviral-treatment drug resistance by gender, age, and other factors in HIV-infected individuals initiating therapy in Kenya, 2013\u20132014","volume":"216","author":"Silverman","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2022.11.012_bib0039","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/cid\/cix1108","article-title":"Effectiveness of protease inhibitor\/nucleos(t)ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the treatment of human immunodeficiency virus type 1 infection in sub-Saharan Africa: a systematic review and meta-analysis","volume":"66","author":"Stockdale","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.11.012_bib0040","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/QAI.0b013e31814258c0","article-title":"Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine","volume":"46","author":"Svarovskaia","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2022.11.012_bib0041","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2022.11.012_bib0042","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1128\/JCM.43.3.1395-1400.2005","article-title":"Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation","volume":"43","author":"Weber","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijid.2022.11.012_bib0043","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1128\/AAC.41.4.757","article-title":"Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years","volume":"41","author":"Winters","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.11.012_bib0044","series-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach","year":"2021"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222005975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222005975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:09:40Z","timestamp":1761120580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222005975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":44,"alternative-id":["S1201971222005975"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.11.012","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N\/R mutation","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}